Susan Galbraith, Executive VP, Oncology R&D, AstraZeneca

As­traZeneca’s on­col­o­gy R&D chief Su­san Gal­braith high­lights their next-gen prospects at #AACR22

As­traZeneca’s turn­around sto­ry rests on the suc­cess of 3 big can­cer drugs: Lyn­parza, Tagris­so and more re­cent­ly En­her­tu. So what’s the fu­ture all about?

The Big Phar­ma’s on­col­o­gy R&D chief Su­san Gal­braith ar­rived at AACR this year with dozens of pre­sen­ta­tions on the ear­ly-stage on­col­o­gy pipeline. And she flagged a few of these as po­ten­tial next-gen ap­proach­es that could help change can­cer treat­ment in the years ahead.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.